ProKidney Corp. is a clinical-stage biotechnology company developing cell therapies for chronic kidney disease. The company's platform centers on rilparencel, an autologous selected renal cell therapy designed to address moderate to severe chronic kidney disease and disease progression in diabetic patients. Rilparencel is currently in Phase 2 and Phase 3 clinical development. The company is also advancing a cryopreserved formulation of rilparencel to extend product shelf life and facilitate use across clinical trials.
The company was founded in 2015 and maintains its headquarters in Winston-Salem, North Carolina. ProKidney operates with approximately 204 full-time employees. As a clinical-stage enterprise, the company does not currently generate product revenue, with development activities representing its primary focus. The company is incorporated in the Cayman Islands and trades on the Nasdaq exchange under the ticker PROK, with a market capitalization of approximately $0.6 billion.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | — | — | — | |
| 2023 | — | — | — | |
| 2022 | $-0.23 | $-0.23 | — | |
| 2021 | — | — | — |